SCHEMBL10043838

SCHEMBL10043838

Cc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3cccs3)ccc1C)c(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 16/20 0.47
MAPT P10636 14/20 0.47
MEN1 O00255 10/20 0.47
KMT2A Q03164 10/20 0.47
ALOX15 P16050 10/20 0.47
TP53 P04637 9/20 0.47
RAB9A P51151 9/20 0.47
HSD17B10 Q99714 8/20 0.47
NPC1 O15118 7/20 0.47
SMN1; SMN2 Q16637 7/20 0.47
GFER P55789 1/20 0.47
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 5/20 0.41
SYK P43405 1/20 0.41
USP2 O75604 2/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043876 0.87 RAB9A (0.42) MAPTMEN1KMT2ARAB9AHSD17B10
SCHEMBL10043821 0.87 SYK (0.49) MAPTMEN1KMT2ATP53RAB9A
SCHEMBL10043828 0.86 RAB9A (0.48) MAPTTP53RAB9ANPC1SMN1; SMN2
SCHEMBL10043831 0.86 NPC1 (0.56) MAPTMEN1KMT2ATP53RAB9A
SCHEMBL10043708 0.86 RAB9A (0.48) MAPTMEN1KMT2ARAB9AHSD17B10
SCHEMBL10043830 0.85 SMARCA2 (0.48) MAPTMEN1KMT2ATP53RAB9A
SCHEMBL10043823 0.83 HTR2C (0.52) MAPTTP53RAB9ANPC1SMN1; SMN2
SCHEMBL10043835 0.82 HTR2A (0.43) MAPTMEN1KMT2ATP53RAB9A
SCHEMBL10043825 0.82 FGFR1 (0.48) GAAMAPTMEN1KMT2ATP53
SCHEMBL10043829 0.82 SYK (0.41) MAPTRAB9ANPC1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC GAA 2883/4885MAPT 2514/4885MEN1 4240/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC GAA 2883/4885MAPT 2514/4885MEN1 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.